LIVNLivaNova PLC
Price
+39%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growth steady, the market undecided.
LivaNova PLC is a market-leading global medical technology company. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.”
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
LivaNova PLC (LIVN) reported revenue of $391M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 70% and net income of $109M (28% of revenue). For the full year FY2025, revenue was $1.39B (+11% year on year) and net income −$242M. Its largest segment in Q2 2026 was Neuromodulation at $127M, 63% of the disclosed total, well ahead of Cardiopulmonary at 37%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jan 14, 2026On January 12, 2026, Michael Hutchinson notified LivaNova PLC (the “Company”) of his resignation as Senior Vice President, Chief Legal Officer, and Company Secretary to pursue another opportunity.Director or officer change · Form 8-K
- Sep 4, 2025Appointment of Director On September 3, 2025, the Board of Directors (the “Board”) of LivaNova PLC (the “Company”) appointed Donald Zurbay to the Board and as a member of the Audit and Compliance Committee of the Board.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $199.3MThe company’s own SEC segment disclosure.
- Neuromodulation$126.6M63%
- Cardiopulmonary$72.8M37%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.